Table 1.
Baseline sociodemographic and clinical characteristics of the patient population
| Patients with NCF/HRQoL data | Patients without NCF/HRQoL data | Original study population | |
|---|---|---|---|
| Patients included, no. (%) | 55 | 42 | 97 |
| Age in years, mean ± SD | 63 ± 9 | 64 ± 12 | 63 ± 11 |
| Sex, no. (%) | |||
| Male | 25 (45%) | 21 (50%) | 46 (47%) |
| Female | 30 (55%) | 21 (50%) | 51 (53%) |
| Educational levela, median (IQR) | 3 (2–4) | 2 (2–4) | 2 (2–4) |
| Brain metastases, no. (%) | |||
| 1 | 21 (38%) | 22 (52%) | 43 (44%) |
| 2 | 23 (42%) | 8 (19%) | 31 (32%) |
| 3 | 9 (16%) | 9 (21%) | 18 (19%) |
| 4 | 2 (4%) | 3 (7%) | 5 (5%) |
| Tumor volume by patient (cm3) | |||
| Median (range)/(IQR) | 7.3 (0.12–63.9)/(3.4–12.8) | 10.2 (0.15-32.0)/(3.6–15.9) | 7.8 (0.12–63.9)/(3.5–14.2) |
| Missing | 1 (2%) | 0 (0%) | 1 (1%) |
| Primary cancer, no. (%) | |||
| Non-small cell lung | 27 (49%) | 20 (49%) | 48 (50%) |
| Renal cell carcinoma | 11 (20%) | 1 (2%) | 12 (13%) |
| Melanoma | 4 (8%) | 5 (12%) | 9 (9%) |
| Colorectal cancer | 3 (5%) | 6 (15%) | 9 (9%) |
| Breast cancer | 3 (5%) | 5 (12%) | 8 (8%) |
| Other | 7 (13%) | 4 (10%) | 10 (10%) |
| Missing | 0 (2%) | 1 (2%) | 1 (1%) |
| Active systemic disease, no. (%) | |||
| Yes | 31 (56%) | 21 (50%) | 52 (54%) |
| No | 24 (44%) | 21 (50%) | 45 (46%) |
| Chemotherapy, no. (%) | |||
| Yes | 6 (11%) | 6 (14%) | 12 (12%) |
| No | 47 (85%) | 33 (79%) | 80 (82%) |
| Missing | 2 (4%) | 3 (7%) | 5 (5%) |
| Extracranial metastases, no. (%) | |||
| Yes | 29 (53%) | 25 (60%) | 54 (56%) |
| No | 25 (45%) | 16 (38%) | 41 (42%) |
| Missing | 1 (2%) | 1 (2%) | 2 (2%) |
| Use of corticosteroids, no. (%) | |||
| Yes | 48 (87%) | 37 (88%) | 85 (88%) |
| No | 4 (7%) | 4 (10%) | 8 (8%) |
| Missing | 3 (5%) | 1 (2%) | 4 (4%) |
| Use of AEDs, no. (%) | |||
| Yes | 12 (22%) | 9 (21%) | 21 (22%) |
| No | 40 (73%) | 32 (76%) | 72 (74%) |
| Missing | 3 (5%) | 1 (2%) | 4 (4%) |
| KPS | |||
| Median (IQR) | 80 (80–90) | 80 (70–80) | 80 (70–90) |
| KPS ≥ 90, No. (%) | 25 (46%) | 9 (21%) | 34 (35%) |
| Missing | 1 (2%) | 0 (0%) | 1 (1%) |
| Survival in months, median (IQR) | 12.0 (8.2–12.0) | 3.8 (1.6–6.4) | 7.7 (3.9–12) |
Due to rounding, not all percentages add up to 100%
aLevel 1–8, NCF neurocognitive functioning, HRQoL health-related quality of life, SD standard deviation, IQR interquartile range, AEDs antiepileptic drugs, KPS Karnofsky performance status